In 1986 Gerald Chan co-founded Morningside, a privately held investment group active in both private equity and venture capital investments in North America, Europe, and Asia. The group began its China investments in 1992 and remains active in China's Internet, media, and life science sectors.
He is currently a board member of the Hang Lung Group, one of the largest real estate companies listed on the Hong Kong Stock Exchange. He serves on the board of several biotechnology companies including Metacure, Matrivax, Critical Biologics, Serica, and Vaccine Technologies Inc. He is a trustee of Fudan University in Shanghai and sits on the advisory boards of the Johns Hopkins University–Nanjing University Center for Chinese and American Studies, the Institute of Mathematical Science of the Chinese University of Hong Kong, and the Physical Sciences Visiting Committee of UCLA.
He received his BS and MS degrees in engineering from UCLA, and a Master of Science degree in medical radiological physics and a Doctor of Science degree in radiation biology from Harvard University. He completed his postdoctoral training at the Dana Farber Cancer Institute.